Hypoglycemic drugs market

Q: What are the key factors hampering growth of the market?

Drug recall is expected to hamper growth of the market. Read more

Hypoglycemic Drugs Market, by Drug Class (Sulphonylureas, Biguanides, Alpha-glucosidase inhibitors, Thiazolidinediones, Dipeptidyl peptidase-4 (DPP-4) inhibitors, and Glucagon), by Route of Administration (Oral, Injectable and Nasal), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Sep 2022
CMI5252
175 Pages
Excel & Pdf
Pharmaceutical

Summary

Hypoglycemia is a condition when blood sugar levels drop below 70 mg/dL. Low blood sugar is especially common in people with type 1 diabetes. Hypoglycemic drugs are anti-diabetic drugs designed to help people with type 1 diabetes manage their condition. The major oral hypoglycemics drug types are:

Biguanides,
Alpha-glucosidase inhibitors,
Sulphonylureas,
Thiazolidinediones (Glitazones)
Dipeptidyl peptidase-4 (DPP-4) inhibitors
Glucagon

Global hypoglycemic drugs market is estimated to be valued at US$ 660 Mn in 2022 and is expected to exhibit a CAGR of 9.2% during the forecast period (2022-2030).

Figure 1. Global Hypoglycemic Drugs Market, in Terms of Value (US$ Million), By Region, 2022

Increasing prevalence of diabetes is expected to drive the global hypoglycemic drugs market growth during the forecast period.

Increasing prevalence of diabetes is expected to drive the global hypoglycemic drugs market growth over the forecast period. For instance, according to a report published by International Diabetes Federation 2021, it is estimated that 1 in 11 adults have diabetes – (61 million), 1 in 3 (36%) people living with diabetes are undiagnosed in Europe, 1 in 7 live births are affected by hyperglycaemia in pregnancy. The Europe Region has the highest number of children and adolescents with type 1 diabetes – 295,000.

Hypoglycemic Drugs Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 660 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	9.2%	2030 Value Projection:	US$ 1,420 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drug Class: Sulphonylureas, Biguanides, Alpha-glucosidase inhibitors, Thiazolidinediones, Dipeptidylpeptidase-4 (DPP-4) inhibitors, Glucagon By Route of Administration: Oral, Injectable, Nasal By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Eli Lilly & Company, Boehringer Ingelheim GmbH, Vistin Pharma AS, Janssen Pharmaceutica NV, Sanofi, Astellas Pharma Inc., AstraZeneca plc., Merck & Co., Inc., Novartis AG., Novo Nordisk A/S, Teva Pharmaceuticals Pvt Ltd., and Sun Pharmaceutical Industries Ltd
Growth Drivers:	Increasing prevalence of diabetes Increasing number of drug approvals from regulatory bodies
Restraints & Challenges:	Drug recalls

Figure 2. Global Hypoglycemic Drugs Market Share (%), By Drug Class, 2022

Increasing product approvals from regulatory bodies is expected to drive the global hypoglycemic drugs market growth over the forecast period.

Market players are focused on gaining approvals from regulatory bodies, which is expected to boost growth of the global hypoglycemic drugs market. For instance, in July 2019, Eli Lilly and Company, a pharmaceutical company, announced that it had received approval from the U.S. Food and Drug Administration, for Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that can be administered without an injection.

Global Hypoglycemic Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

COVID-19 has resulted in several challenges in healthcare sector. Due to lockdown it created disruptions for the patients to visit Diabetic centers. According to an article published by Diabetes Canada, University Avenue, Canada in 2021, a study was conducted by researchers of University Avenue for the situation of diabetic patients during COVID-19. It was concluded that the rates of hypoglycemia appeared to be mixed, depending on type of diabetes. Data from Spain and Italy, examining glycemic management during the early days of lockdown, showed either no change in the frequency incidence of hypoglycemia in adults with type 1 diabetes or a decrease in the hypoglycemic events. In an Italian study of children with type 1 diabetes, there was a slight decrease in the number of cases of severe hypoglycemia reported in 2020 versus the same time period in 2019. Moreover, another Spanish study also reported no significant increase in hypoglycemiacfor people with type 1 diabetes.

Global Hypoglycemic Drugs Market: Restraints

Drug recalls from market players are expected to hinder growth of the global hypoglycemic drugs market. For instance, in June 2021, US FDA had alerted patients and health care professionals about Nostrum Laboratories’ voluntary recall of one additional lot of extended release (ER) metformin. The company had recalled the lot because the metformin may have contained N-nitrosodimethylamine (NDMA) above the acceptable intake limit.

Similarly, in May 2020, Marksans Pharma and Sun Pharmaceutical Industries Limited., announced voluntary recall of extended release (ER) metformin. The companies had recalled metformin because it may have contained N-nitrosodimethylamine (NDMA) above the acceptable intake limit.

Key Players

Major players operating in the global hypoglycemic drugs market include Eli Lilly & Company, Boehringer Ingelheim GmbH, Vistin Pharma AS, Janssen Pharmaceutica NV, Sanofi, Astellas Pharma Inc., AstraZeneca plc., Merck & Co., Inc., Novartis AG., Novo Nordisk A/S, Teva Pharmaceuticals Pvt Ltd., and Sun Pharmaceutical Industries Ltd.

Table of Content

Table of Contents

*Browse 39 market data tables and 22 figures on "Global Hypoglycemic Drugs Market” - Forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global hypoglycemic drugs market during the forecast period (2022-2030)?

Global hypoglycemic drugs market is estimated to be valued at US$ 660 million in 2022 and is expected to exhibit a CAGR of 9.2% between 2022 and 2030.

What are the major factors driving the market growth?

Increasing prevalence of diabetes and increasing product approvals from regulatory bodies are expected to drive the market growth over the forecast period.

Which is the leading Drug class segment in the market?

Biguanides segment is holding a major market share in the market.

What are the key factors hampering growth of the market?

Drug recall is expected to hamper growth of the market.

Which are the major players operating in the market?

Major players operating in the market include Eli Lilly & Company, Boehringer Ingelheim GmbH, Vistin Pharma AS, Janssen Pharmaceutica NV, Sanofi, Astellas Pharma Inc., AstraZeneca plc., Merck & Co., Inc., Novartis AG., Novo Nordisk A/S, Teva Pharmaceuticals Pvt Ltd., and Sun Pharmaceutical Industries Ltd.